Effect of octreotide on polycystic liver volume

摘要

To the Editor:Polycystic livers can be present in combination with polycystic kidneys termed autosomal dominant polycystic kidney disease (1), or in an isolated form: autosomal dominant polycystic liver disease (PCLD). Symptoms arise as a result of large liver volume and treatment is directed to volume reduction and current options are invasive by nature (2-5).Experimental evidence suggests that octreotide reduces liver and kidney volume in rodents with PCLD (6). We reported previously that a 3- to 6-month somatostatin analogue treatment of two polycystic liver patients decreased liver volume (7). This stimulated us to evaluate the effect of octreotide in a larger series.